跳至主要内容
临床试验/NCT02111681
NCT02111681已完成不适用

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer

Memorial Sloan Kettering Cancer Center8 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2014年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
8
主要终点
Feasibility of Calypso Transponders

研究概览

简要总结

The purpose of this study is to test the use of Calypso beacon implants as a way to determine where the lung tumor is located during radiation treatment. The Calypso beacons are small devices that are implanted in the lungs, near the tumor. They are able to send a signal to a tracking system to show where they are, and where the tumor is, as the patient holds their breath for the radiation treatment. The investigators want to find out what effects, good and/or bad, that this has on the patient and the way they treat the cancer in your lungs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have histologic proof of malignancy suitable for thoracic radiation therapy
  • Patients planning to undergo radiation therapy for primary or recurrent malignancy of the lung or metastatic malignancy to the lung.
  • Age ≥ 18 years old
  • KPS ≥ 60%
  • Ability to hold their breath for >20 seconds for 5 times
  • Patients who are able to tolerate flexible bronchoscopy
  • Patients with life expectancy of at least 12 months
  • Patients able to have bronchoscopic placement of Calypso as confirmed on a recent (within the past 8 weeks) CT scan.
  • Patients who are able to comply with the protocol follow-up schedule.

排除标准

  • Patients unable to comply with instructions for DIBH
  • Patients with implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization.
  • Patients with active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown.
  • Patients with clinically significant active infections.
  • Patients with bronchiectasis in the region of the intended implantation sites.
  • Patients with a history of hypersensitivity to nickel.
  • Patients whose lung tumors are being monitored with MR imaging (MR imaging of the anchored transponders is safe but yields an image artifact around the anchored transponders).
  • Posterior lesions that would be >19cm distance from Calypso detector plate. Patients may be treated in the prone position in order to meet the required minimum distance.
  • Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.
  • Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy
  • Patients who are unable to tolerate anesthesia or sedation
  • Patients enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.
  • Female patients who are pregnant or nursing

结局指标

主要结局

Feasibility of Calypso Transponders

时间窗: 2 years

Feasibility is defined as completion of all treatments using the DIBH treatment plan and Calypso transponders.

次要结局

  • Reproducibility(2 years)
  • Measure the Residual Intrafraction Tumor Motion(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验